Stock Taper
SCREENER COMPARE ANY 2 STOCKS
GDTC
CYTOMED THERAPEUTICS LIMITED
NASDAQ
$0.86
▼ DOWN 2.15% (-0.02)

KEY STATISTICS

Market Cap$10.19 M
52w High$3.68
52w Low$0.68
Dividend Yield—
Frequency—
P/E-3.99
Volume16.61K
Shares Out.11.83M

COMPANY

LEADERSHIP

Chee Kong Choo
CHIEF EXECUTIVE
Chee Kong Choo

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 14, 2023
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
42

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.—
NOV
13
FRI

PRICE

$0.86 ▼ DOWN 2.15% (−$0.02)
$0.85$0.88$0.90$0.939:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM0.86

About CytoMed Therapeutics Limited

https://w2.cytomed.sg ↗

CytoMed Therapeutics Limited, a Singapore-based pre-clinical biopharmaceutical company founded in 2018, develops novel cell-based immunotherapies like CTM-N2D, iPSC-gdNKT, and CTM-GDT to treat various human cancers.

INDUSTRY

Biotechnology

A PRODUCT CYTOMED THERAPEUTICS LIMITED IS KNOWN FOR

CAR-γδ T cell therapy
CAR-γδ T cell therapy

CytoMed's lead allogeneic CAR-gamma delta T cell therapy aims to treat various cancers and is currently in a Phase I clinical trial in Singapore.

COMPETITORS

COMPETITOR
ACET COMPARE
ALLO COMPARE
AUTL COMPARE
FATE COMPARE

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score1

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
Choo Chee Kong
Purchase · 100.0K shares
2026-07-20
★
DIRECTOR, 10 PERCENT OWNER:
Choo Chee Kong
Purchase · 112.0K shares
2026-05-13
★
DIRECTOR
Toh Keng Kiat
— · —
2026-03-18
★
DIRECTOR, 10 PERCENT OWNER:
Choo Chee Kong
— · —
2026-03-18

SECTORS PEERS

PEERPRICE
NRXS$5.96COMPARE
ENLV$1.10COMPARE
NRSN$0.48COMPARE
LSTA$1.69COMPARE
PASG$4.72COMPARE
NCNA$1.41COMPARE
XCUR$1.25COMPARE
CLGN$3.65COMPARE